Angiogenin mutants as novel effector molecules for the generation of fusion proteins with increased cytotoxic potential
- PMID: 25710248
- DOI: 10.1097/CJI.0000000000000053
Angiogenin mutants as novel effector molecules for the generation of fusion proteins with increased cytotoxic potential
Abstract
Human cytolytic fusion proteins (hCFPs) are therapeutically efficacious recombinant polypeptides comprising a target cell-specific binding component and a human effector domain that induces apoptosis. Compared with former generations of immunotoxins, which contain immunogenic cytotoxic domains derived from bacteria or plants, hCFPs contain solely human proteins that do not induce an immune response, thus avoiding the development of neutralizing antibodies. Here, we investigated the suitability of human angiogenin (Ang) mutants as effector domains. We engineered 3 different Ang variants that outperformed the wild-type enzyme by replacing amino acid residues with key roles in the protein's catalytic activity and its interaction with the ribonuclease inhibitor RNH1. The cytotoxic potential of these mutants was compared with wild-type Ang by fusing each to the CD64-specific single-chain variable fragment H22. All hCFPs were successfully expressed in HEK293T cells and purified from the cell culture supernatant by immobilized metal ion affinity chromatography. The Ang mutant-based hCFPs showed normal binding activity towards human interferon-γ-stimulated CD64 HL-60 cells and activated human macrophages isolated from peripheral blood mononuclear cells, but increased cytotoxicity based on reduced affinity towards RNH1 and higher ribonucleolytic activity.
Similar articles
-
Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo.Cancer Immunol Immunother. 2015 Dec;64(12):1575-86. doi: 10.1007/s00262-015-1763-8. Epub 2015 Oct 15. Cancer Immunol Immunother. 2015. PMID: 26472728 Free PMC article.
-
Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells.Cancer Lett. 2013 Dec 1;341(2):178-85. doi: 10.1016/j.canlet.2013.08.005. Epub 2013 Aug 22. Cancer Lett. 2013. PMID: 23973499
-
Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.Cancer Res. 2001 Dec 15;61(24):8737-42. Cancer Res. 2001. PMID: 11751393
-
Angiogenin (ANG)-Ribonuclease Inhibitor (RNH1) System in Protein Synthesis and Disease.Int J Mol Sci. 2021 Jan 28;22(3):1287. doi: 10.3390/ijms22031287. Int J Mol Sci. 2021. PMID: 33525475 Free PMC article. Review.
-
Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation.Biomedicines. 2017 Feb 17;5(1):9. doi: 10.3390/biomedicines5010009. Biomedicines. 2017. PMID: 28536352 Free PMC article. Review.
Cited by
-
Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells.Oncotarget. 2019 Jan 25;10(8):897-915. doi: 10.18632/oncotarget.26618. eCollection 2019 Jan 25. Oncotarget. 2019. PMID: 30783518 Free PMC article. Review.
-
Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells.Biomedicines. 2018 Mar 5;6(1):28. doi: 10.3390/biomedicines6010028. Biomedicines. 2018. PMID: 29510557 Free PMC article. Review.
-
Antibody-Based Immunotoxins for Colorectal Cancer Therapy.Biomedicines. 2021 Nov 19;9(11):1729. doi: 10.3390/biomedicines9111729. Biomedicines. 2021. PMID: 34829955 Free PMC article. Review.
-
Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo.Cancer Immunol Immunother. 2015 Dec;64(12):1575-86. doi: 10.1007/s00262-015-1763-8. Epub 2015 Oct 15. Cancer Immunol Immunother. 2015. PMID: 26472728 Free PMC article.
-
CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL.Biomedicines. 2017 Jun 28;5(3):37. doi: 10.3390/biomedicines5030037. Biomedicines. 2017. PMID: 28657611 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous